Table 2.
Trastuzumab-Based Therapy Information and Clinical Outcomes of the 137 Metastatic Breast Cancer Patients
| Variable | Description |
|---|---|
| Ttzm-based therapy | |
| Ttzm single agent | 16 (11.7%) |
| Ttzm + navelbine | 30 (21.9%) |
| Ttzm + taxane-based chemotherapy | 76 (55.5%) |
| Ttzm + other therapy | 15 (10.9%) |
| Lines of Ttzm-based therapy | |
| First-line | 87 (63.5%) |
| Second-line | 26 (19.0%) |
| Other | 24 (17.5%) |
| Prior chemotherapy | |
| Without | 91 (66.4%) |
| With | 39 (28.5%) |
| Unknown | 7 (5.1%) |
| Response to Ttzm-based therapy | |
| CR + PR + SD | 82 (59.9%) |
| PD | 55 (40.1%) |
| Outcome | |
| Dead | 97 (70.8%) |
| Alive | 40 (29.2%) |
| Median time of overall survival from Ttzm-based therapy start date | 23m (range 1–84 m) |
| Patients responsive (CR + PR + SD) to therapy | 30m (range 2–84 m) |
| Patients resistant (PD) to therapy | 13m (range 1–49 m) |
Ttmz indicates trastuzumab; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease.